A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 14 Nov 2017 Planned number of patients changed from 50 to 55.
- 20 Jun 2017 Planned primary completion date changed from 15 Jun 2017 to 31 Jan 2018.
- 10 Jun 2017 Biomarkers information updated